Perjeta drug approved

There is good news this week for the 1,400 women a year who suffer from the aggressive HER2-positive breast cancer. Nice have now approved the use of the drug Perjeta, (the Roche brand name for pertuzumab), following the pharma manufacturer’s agreement to drop the price for NHS use.

The drug Perjeta is used in combination with Herceptin, (Roche’s brand name for trastuzumab), and can shrink tumours that were previously inoperable, enabling them to be surgically removed.

No Comments Yet.

Leave a reply